Silence Therapeutics Statistics
Total Valuation
SLN has a market cap or net worth of $324.84 million. The enterprise value is $152.14 million.
Important Dates
The last earnings date was Thursday, November 14, 2024, before market open.
Earnings Date | Nov 14, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
SLN has 47.21 million shares outstanding. The number of shares has increased by 21.51% in one year.
Current Share Class | n/a |
Shares Outstanding | 47.21M |
Shares Change (YoY) | +21.51% |
Shares Change (QoQ) | +0.71% |
Owned by Insiders (%) | 26.36% |
Owned by Institutions (%) | 43.73% |
Float | 25.62M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 13.96 |
Forward PS | n/a |
PB Ratio | 2.56 |
P/TBV Ratio | 2.79 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 6.99 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.31, with a Debt / Equity ratio of 0.00.
Current Ratio | 9.31 |
Quick Ratio | 8.61 |
Debt / Equity | 0.00 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -102.80% and return on invested capital (ROIC) is -63.40%.
Return on Equity (ROE) | -102.80% |
Return on Assets (ROA) | -27.27% |
Return on Capital (ROIC) | -63.40% |
Revenue Per Employee | $199,754 |
Profits Per Employee | -$723,788 |
Employee Count | 109 |
Asset Turnover | 0.12 |
Inventory Turnover | n/a |
Taxes
Income Tax | -9.47M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.93% in the last 52 weeks. The beta is 1.04, so SLN's price volatility has been similar to the market average.
Beta (5Y) | 1.04 |
52-Week Price Change | -58.93% |
50-Day Moving Average | 12.66 |
200-Day Moving Average | 18.32 |
Relative Strength Index (RSI) | 32.22 |
Average Volume (20 Days) | 691,088 |
Short Selling Information
Short Interest | 702,326 |
Short Previous Month | 381,473 |
Short % of Shares Out | 1.49% |
Short % of Float | 2.74% |
Short Ratio (days to cover) | 2.36 |
Income Statement
In the last 12 months, SLN had revenue of $21.77 million and -$78.89 million in losses. Loss per share was -$1.79.
Revenue | 21.77M |
Gross Profit | 9.75M |
Operating Income | -78.16M |
Pretax Income | -52.45M |
Net Income | -78.89M |
EBITDA | -77.75M |
EBIT | -78.16M |
Loss Per Share | -$1.79 |
Full Income Statement Balance Sheet
The company has $172.89 million in cash and $186,302 in debt, giving a net cash position of $172.70 million or $3.66 per share.
Cash & Cash Equivalents | 172.89M |
Total Debt | 186,302 |
Net Cash | 172.70M |
Net Cash Per Share | $3.66 |
Equity (Book Value) | 126.68M |
Book Value Per Share | 2.68 |
Working Capital | 188.45M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$58.75 million and capital expenditures -$156,815, giving a free cash flow of -$55.24 million.
Operating Cash Flow | -58.75M |
Capital Expenditures | -156,815 |
Free Cash Flow | -55.24M |
FCF Per Share | -$1.17 |
Full Cash Flow Statement Margins
Gross Margin | 44.78% |
Operating Margin | -358.97% |
Pretax Margin | -405.85% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
SLN does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -21.51% |
Shareholder Yield | -21.51% |
Earnings Yield | -24.29% |
FCF Yield | -17.00% |
Analyst Forecast
The average price target for SLN is $61.50, which is 793.90% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $61.50 |
Price Target Difference | 793.90% |
Analyst Consensus | Strong Buy |
Analyst Count | 4 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
SLN has an Altman Z-Score of 2.07 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.07 |
Piotroski F-Score | 3 |